Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Caris Life Sciences, Inc. (CAI) Institutional Ownership & Insider Trading

246 institutions reported holding Caris Life Sciences, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 11 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CAICaris Life Sciences, Inc.Follow CAI — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
9.0B
P/E TTM
85.6
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

246 institutions held 54.5% of the shares. Across filers that reported both quarters, shares held changed -1.8%.

Increased+101New+62Decreased-45Closed-19

Largest moves, shares (millions)

JPMorgan Chase+3.1MMak Capital One+1.9MLos Angeles Capital…+1.7MSixth Street Partners…-7.1MJ. H. Whitney Equity…-7.0MT. Rowe Price Associates-3.2M

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters
+0.0Jun 25+5.3Sep 25+15.2Dec 25+0.7Mar 26-2.8Jun 26
QuarterHoldersShares held, MChangeIncreasedNewDecreasedClosed
Jun 26246154-1.8%101624519
Mar 26201157+0.4%86493833
Dec 25186149+13.4%63692924
Sep 25137114+4.9%46521829
Jun 25115109—————

Caris Life Sciences, Inc. — questions

Who owns Caris Life Sciences, Inc. stock?
246 institutions reported Caris Life Sciences, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (10.9%), J. H. Whitney Equity Partners VI, LLC (4.0%), COATUE MANAGEMENT LLC (3.5%).
Are Caris Life Sciences, Inc. insiders buying or selling?
11 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.